Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Mar

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Partial Gland Removal May Be an Option for Many Men With Prostate Cancer

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Greater Plant Based Oil Lower Butter Intake Could Improve Risk of Cancer Related Mortality

Breast Cancer Mortality Rates May Have Stopped Declining

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer